Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Myeloma
79%
Chemotherapy
62%
Chronic Myeloid Leukemia
53%
Human Pluripotent Stem Cells (hPSCs)
51%
South Korea
51%
Bortezomib
51%
Induced Pluripotent Stem Cells (iPSCs)
50%
Pluripotent Stem Cell Line
43%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
39%
CD34+
38%
Multiple Myeloma Patients
38%
Treatment Outcome
35%
Overall Survival
35%
Cisplatin
34%
Leucovorin
34%
Lens-free Shadow Imaging Technology
34%
Neutropenia
32%
Imatinib Mesylate
32%
Cell-conditioned Medium
31%
Cyclophosphamide
31%
Placenta Cells
30%
Human Mesenchymal Stem Cells (hMSCs)
29%
Platelet Count
29%
Combination Chemotherapy
28%
Newly Diagnosed
28%
Diffuse Large B-cell Lymphoma (DLBCL)
28%
Prognostic Value
27%
CXCR2
26%
Acute Myeloid Leukemia
25%
Programmed Death-ligand 1 (PD-L1)
25%
C(X)
25%
Anthracyclines
25%
Receptor 2
25%
Bone Marrow
24%
Stem Cells
24%
Leukemia Patients
24%
Risk Factors
23%
5-fluorouracil (5-FU)
23%
Imatinib
22%
Human Placenta
22%
95% Confidence Interval
22%
Granulocyte Colony-stimulating Factor (G-CSF)
21%
Autologous Stem Cell Transplantation (auto-SCT)
20%
Human Embryonic Stem Cells (hESCs)
20%
Mammalian Target of Rapamycin (mTOR)
19%
Adult Patients
18%
Cytomegalovirus Reactivation
18%
Advanced Gastric Cancer
18%
Natural Killer Cells
18%
Mesenchymal Stem Cells
18%
Medicine and Dentistry
Chemotherapy
99%
Multiple Myeloma
80%
Overall Survival
76%
Cisplatin
45%
Platelet
44%
Treatment Outcome
44%
NK T Cell Lymphoma
42%
Progression Free Survival
39%
Prognostic Factor
34%
Anemia
34%
Myelodysplastic Syndrome
34%
Folinic Acid
34%
Autologous Stem Cell Transplantation
33%
Diseases
31%
Non-Hodgkin Lymphoma
30%
Bortezomib
27%
Abdominal Cancer
27%
Neutropenia
27%
Diffuse Large B-Cell Lymphoma
26%
Vasculotropin
25%
Aplastic Anemia
25%
Cytomegalovirus
25%
Fluorouracil
25%
Survival Rate
23%
Malignant Neoplasm
22%
Ferritin
19%
Etoposide
19%
Risk Stratification
19%
Myeloma
19%
Combination Chemotherapy
19%
Febrile Neutropenia
19%
Long Term Survival
18%
Epirubicin
18%
Leukemia
18%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Natural Killer Cell
18%
Hazard Ratio
18%
Multivariate Analysis
17%
Hematopoietic Stem Cell Transplantation
17%
Observational Study
17%
Stem Cell Mobilization
17%
Cohort Analysis
17%
Idiopathic Thrombocytopenic Purpura
17%
Eculizumab
17%
Paroxysmal Nocturnal Hemoglobinuria
17%
Hematopoietic Cell
15%
Neuropathy
15%
Lymphocyte
15%
Prednisone
14%
Stem Cell
13%
Immunology and Microbiology
Multiple Myeloma
100%
Overall Survival
58%
Placenta
55%
CD34
43%
Human Embryonic Stem Cell
42%
Programmed Death 1 Ligand 1
42%
Hematopoietic Cell
37%
B Cell
34%
Immunoglobulin Producing Cell
29%
Pluripotent Stem Cell
27%
Drug Megadose
26%
Stem Cell Line
25%
Induced Pluripotent Stem Cell
25%
Dioxygen
25%
Progression Free Survival
25%
Platelet Count
24%
Fibroblast Growth Factor 2
21%
Cyclophosphamide
20%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Feeder Cell
18%
Pretreatment
18%
Pluripotent Stem Cell Line
18%
Exosome
17%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Lens
17%
Intravenous Immunoglobulin
17%
Cytomegalovirus
17%
Aplastic Anemia
17%
Vasculotropin
17%
Dexamethasone
17%
Steroid
17%
In Vitro
16%
Lymphocyte
16%
Fibroblast
15%
Infectious Disease
15%
Infection
15%
Blood Plasma
15%
Neutrophil
15%
Blood Level
14%
Programmed Death-Ligand 1
14%
Stem Cell
14%
Embryoid Body
14%
Mesenchymal Stem Cell
12%
Acute Graft Versus Host Disease
12%
Autologous Stem Cell Transplantation
12%
Mononuclear Cell
12%
Cell Line
12%
Platelet
11%
Cell Culture Technique
11%
Tumor Cell
10%